CAM 183

BRINEURA (cerliponase alfa)

Category:Prescription Drug   Last Reviewed:January 2021
Department(s):Medical Affairs   Next Review:January 2022
Original Date:January 2018    

Description
Brineura is a hydrolytic lysosomal N-terminal tripeptidyl peptidase indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.

Policy 
Brineura (cerliponase alfa) is considered MEDICALLY NECESSARY in the treatment of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2)   for ALL of the following criteria are met:

  1. Diagnosis of CLN2 was confirmed by enzyme assay demonstrating a deficiency of tripeptidyl peptidase 1 (TPP1) enzyme activity or by genetic testing.
  2. Member is 3 years of age or older
  3. Brineura will be administered by, or under the direction of a physician knowledgeable in intraventricular administration
  4. Patient does not have acute intraventricular access-related complications (e.g., leakage, device failure, or device-related infections)
  5. Patient does not have ventriculoperitoneal shunts
  6. Prescribed by or in consultation with a neurologist with expertise in the diagnosis of CLN2/ TTP1 Deficiency

Continuation 

  1. Patient does not have acute intraventricular access-related complications (e.g., leakage, device failure, or device-related infections) AND
  2. Patient does not have ventriculoperitoneal shunts AND
  3. Patient has experienced a benefit from therapy (e.g., improvement in walking or crawling, or no evidence of disease progression)

Dosage 

  • Aseptic technique must be strictly observed during preparation and administration. Brineura should be administered by, or under the direction of, a physician knowledgeable in intraventricular administration. Brineura is administered to the cerebrospinal fluid (CSF) by infusion via a surgically implanted reservoir and catheter.  
  • Pre-treatment of patients with antihistamines with or without antipyretics or corticosteroids is recommended 30 to 60 minutes prior to the start of infusion.
  • The recommended dosage is 300 mg administered once every other week as an intraventricular infusion, followed by infusion of intraventricular electrolytes over approximately 4.5 hours.  
  • For complete information on preparation, specific intraventricular access device for use, and administration, see the full prescribing information.

Coding Section 

Code Number Description
HCPCS C9014 Injection, cerliponase alfa, 1 mg
  J3590 Unclassified biologics
  J3490  Unclassified Drugs 
ICD-10 Diagnosis Code E75.4 Neuronal ceroid lipofuscinosis

References 

  1. Brineura™ (cerliponase alfa). [Prescribing Information]. BioMarin Pharmaceutical Inc. Novato, CA. April 2017.
  2. ClinicalTrials.gov. A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease. Available from: https://clinicaltrials.gov/ct2/show/NCT01907087?term=NCT01907087&rank=1. Accessed April 29, 2017.
  3. U.S. Food and Drug Administration. FDA News Release: FDA approves first treatment for a form of Batten disease. [Online]. April 27, 2017. Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm555613.htm
  4. ClinicalTrials.gov. A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease. Available from: https://clinicaltrials.gov/ct2/show/NCT02485899?term=NCT02485899&rank=1. Accessed April 29, 2017. 
  5. Geraets RD, Koh SY, Hastings ML, et al. Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis. Orphanet J Rare Dis. 2016; 11:40.
  6. Worgall S, Kekatpure MV, Heier L, et al. Neurological deterioration in late infantile neuronal ceroid lipofuscinosis. Neurology. 2007; 69(6):521-535.
  7. BioMarin Pharmaceutical. A multicenter, multinational, extension study to evaluate the long-term efficacy and safety of BMN 190 in patients with CLN2 disease. NLM Identifier: NCT02485899. Last updated on October 28, 2016. Available at: https://clinicaltrials.gov/ct2/show/NCT02485899?term=cerliponase+alfa&rank=2 . Accessed on July 10, 2017.
  8. BioMarin Pharmaceutical. A phase 1/2 open-label dose-escalation study to evaluate safety, tolerability, pharmacokinetics, and efficacy of intracerebroventricular BMN 190 in patients with late-infantile neuronal ceroid lipofuscinosis (CLN2) disease. NLM Identifier: NCT01907087. Last updated on April 25, 2016. Available at: https://clinicaltrials.gov/ct2/show/NCT01907087?term=cerliponase+alfa&rank=1 . Accessed on July 10, 2017.
  9. Brineura[Product Information], San Rafael, CA. Biomarin, April 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761052lbl.pdf . Accessed on July 10, 2017.
  10. Cerliponase alfa. In: DrugPoints System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated April 27, 2017. Available at: http://www.micromedexsolutions.com. Accessed on July 10, 2017.
  11. National Institute of Neurological Disorders and Stroke. Batten disease fact sheet. 2011. Available at: http://www.ninds.nih.gov/disorders/batten/detail_batten.htm. Accessed on July 10, 2017. 

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross and Blue Shield Association technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

"Current Procedural Terminology © American Medical Association.  All Rights Reserved" 

History From 2018 Forward     

01/19/2021 

Annual review, no change to policy intent. 

01/27/2020 

Annual review, adding medical necessity criteria 4-6 in addition to the existing criteria 1-3. Also adding criteria for continuation of medication. 

01/02/2019 

Annual review, no change to policy intent. 

01/08/2018

New Policy

 


Go Back